about
Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependenceA review of a national training initiative to increase provider use of MAT to address the opioid epidemic.Dextromethorphan and quinidine combination for heroin detoxification.Brain levels of dextromethorphan and the intensity of opioid withdrawal in mice.A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence.Betting on change: modeling transitional probabilities to guide therapy development for opioid dependence.In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists.From AIDS to Opioids - How to Combat an EpidemicA randomized, double-blind, placebo-controlled trial of venlafaxine for the treatment of depressed cocaine-dependent patients.A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period.Management of relapse in naltrexone maintenance for heroin dependence.Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment.Memantine reduces consumption of highly palatable food in a rat model of binge eatingOpen-label pilot study of quetiapine treatment for cannabis dependence.Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR?Comparison of clinical trial recruitment populations: treatment-seeking characteristics of opioid-, cocaine-, and cannabis-using participantsOpioid detoxification and naltrexone induction strategies: recommendations for clinical practice.A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexoneBaseline characteristics of patients predicting suitability for rapid naltrexone induction.Comparison of substance use milestones in cannabis- and cocaine-dependent patients.Evaluation of potential sex differences in the subjective and analgesic effects of morphine in normal, healthy volunteersThe effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.Effects of major depressive disorder and attention-deficit/hyperactivity disorder on the outcome of treatment for cocaine dependence.Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.Assessment of riboflavin as a tracer substance: comparison of a qualitative to a quantitative method of riboflavin measurement.Effects of levodopa-carbidopa-entacapone and smoked cocaine on facial affect recognition in cocaine smokers.A comparison of independent depression and substance-induced depression in cannabis-, cocaine-, and opioid-dependent treatment seekersA randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disordersExtended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial.Antagonism of glutamatergic NMDA and mGluR5 receptors decreases consumption of food in baboon model of binge-eating disorder.Cognition, commitment language, and behavioral change among cocaine-dependent patientsAcute interaction of baclofen in combination with alcohol in heavy social drinkersAntisocial behavioral syndromes in cocaine and cannabis dependence.Atomoxetine Treatment for Cocaine Abuse and Adult Attention-Deficit Hyperactivity Disorder (ADHD): A Preliminary Open Trial.A novel procedure for assessing the effects of drugs on satiation in baboons: effects of memantine and dexfenfluramine.Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders.Cognitive deficits predict low treatment retention in cocaine dependent patients.Ling et al.'s 'Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder'.
P50
Q24645054-B36AF657-7014-42D7-BB60-557614181FF1Q30239840-AF7645D6-A97C-45BA-B149-D58277A6D31CQ30418597-FE35E5E1-FD42-4F68-92E9-50D2ADDF9C55Q33323106-4C26B76A-CF24-4E57-8708-E6AFCC54B6E3Q33556479-84D518A3-3B48-4B3F-A053-6E1F72CB50C2Q33704889-800BC2C5-ABE9-46B0-A08E-2577C6907262Q33856557-BBB19E5A-2249-4788-BD96-2EAB7989E4F4Q33918193-7244CBFB-A6D4-4FF3-8767-B2681ED320DDQ34049083-B02610CA-A3C0-4036-975E-B3BEEC4F9BF1Q34091611-6185079F-98AA-4236-8166-04A2DA363C75Q34128519-29D4E050-A3E1-4897-A72C-301273EDC77CQ34280076-2A049629-59CF-4002-9B43-87741A6DEEB8Q34486676-19B3D349-C651-4DBA-8DAD-49CD71F0E3F1Q34512547-0A92BEF2-ACE9-4145-9514-8C912C804A94Q34615910-5B7050E4-309E-402A-9B48-64948FB3BC30Q34852203-0610CC51-883A-490E-91B4-606857A774D2Q35090939-3CA34FE9-A8C8-42B3-8071-E9D5F2041BEAQ35417660-57163318-EBEF-467C-AF25-896FD8552D8EQ35619851-D2D5E143-F8AC-4A0B-8505-82084C79D4A3Q35834292-68A6B79E-1969-4C1C-97F1-340DAB088507Q35841834-DEF9EAF5-C715-409C-9D6A-9761BFC53AFDQ35873873-EF377A8A-D350-469C-834F-6C424C3EE7E6Q35952033-54224283-2796-438D-A7E1-657BE4A5ADCAQ36478373-75C851B5-251C-4A8A-8B33-29E0A85C9BECQ36509285-68CAF0F2-0C35-4799-B753-9759CA9D8A03Q36567029-D3BD5CF5-0029-4691-9EA1-F3AD1AD96602Q36693056-0CBC1295-4EA8-4828-9632-E41E49521038Q36693941-921BD974-DEAF-480C-8817-CA01DD8E90EAQ36794579-335A83E0-741D-473A-ABA4-83CFE2A8C72BQ36829186-221A2FF4-7FC3-4B73-A7C0-C350705D261FQ36991828-3C36C864-0599-4137-BCCD-0FEAD7D42875Q37019735-05FFDC03-A8AE-4DF6-8163-7BC60C6A6003Q37060525-FB832427-1F9F-4324-9787-0DA3928E5890Q37178464-501EF046-64B1-460F-9B55-E064ECC23D06Q37185366-03C5AC33-6BE4-4DB6-9A92-FC8A3F76A630Q37255442-F60E89E8-6E20-4598-BD72-D875D1FAC9A8Q37638805-7C4185DA-508E-4B39-ADC1-280EB0C204B7Q39192957-AE431DD7-B42F-4ECC-8909-69C89C778A45Q40387821-590BA371-F7F3-478B-A13B-43CDFE1EDD17Q42358768-13219180-CCD9-41AA-BDBC-4FFF0AB2B48D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Adam Bisaga
@ast
Adam Bisaga
@en
Adam Bisaga
@es
Adam Bisaga
@nl
Adam Bisaga
@sl
type
label
Adam Bisaga
@ast
Adam Bisaga
@en
Adam Bisaga
@es
Adam Bisaga
@nl
Adam Bisaga
@sl
prefLabel
Adam Bisaga
@ast
Adam Bisaga
@en
Adam Bisaga
@es
Adam Bisaga
@nl
Adam Bisaga
@sl
P106
P21
P31
P496
0000-0003-4243-6462